Market Research Report - 216700
Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)
|Published by||GBI Research|
|Published||Content info||111 Pages|
|Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)|
|Published: October 15, 2012||Content info: 111 Pages||
The global Diabetic Macular Edema (DME) market will expand massively in the near future as a result of lifestyle changes and the introduction of more effective (and more expensive) treatments, says the latest report from pharmaceutical industry experts GBI Research.
According to their new research*, the business intelligence providers expect the global DME market to climb exponentially in value, from $43m in 2011 to a far greater $985m in 2018, exhibiting a Compound Annual Growth Rate (CAGR) of 57%.
Such dramatic growth is primarily attributed to the entrance of key treatments, including Novartis's Lucentis, which gained approval from the European Commission early last year and the US Food and Drug Administration (FDA) this year.
These approval decisions were backed by data from two Novartis-funded clinical trials, RESTORE and RESOLVE, that demonstrated that Lucentis was superior in visual acuity gain versus sham (dummy therapy) or laser therapy - the current standard of care.
Global DME market growth is predicted to be further supported by Alimera's Iluvien and Allergan's Ozurdex. The former gained European approval in June, and will be available for commercial launch by the end of the year, but was rejected by the FDA late last year over safety concerns. Ozurdex, a promising biodegradable implant, is expected to receive FDA approval in 2015.
The global ophthalmology market as a whole is expected to perform far less impressively than its DME portion, primarily due to the impending patent expiries of prostaglandin analogs used in the treatment of glaucoma.
Global industry revenue will climb, however modestly, from $10 billion in 2011 to $12 billion in 2018, at a CAGR of 2.8%.
*Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD).
This report provides insights into the global ophthalmology therapeutics market, with forecasts until 2018.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.